scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1038208710 |
P356 | DOI | 10.1007/S10096-016-2809-3 |
P698 | PubMed publication ID | 27848039 |
P50 | author | Theodore Lytras | Q58485725 |
Emmanouil Antalis | Q88424871 | ||
Sotiris Tsiodras | Q37830054 | ||
P2093 | author name string | A Meijer | |
P Karakitsos | |||
A-F A Mentis | |||
K Tryfinopoulou | |||
A F Mentis | |||
A Kossyvakis | |||
A Kalliaropoulos | |||
V Pogka | |||
P2860 | cites work | The epidemiology and spread of drug resistant human influenza viruses | Q38215346 |
NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots. | Q41030411 | ||
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. | Q41344703 | ||
Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats | Q43166298 | ||
Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient | Q43186856 | ||
Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. | Q44616840 | ||
Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. | Q45369153 | ||
Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine | Q45382232 | ||
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. | Q45947329 | ||
Community Transmission of Oseltamivir-Resistant A(H1N1)pdm09 Influenza | Q57077387 | ||
Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012 | Q95438587 | ||
Neuraminidase inhibitors for preventing and treating influenza in adults and children | Q24197463 | ||
MEGA6: Molecular Evolutionary Genetics Analysis version 6.0 | Q24498082 | ||
Acute emergence and reversion of influenza A virus quasispecies within CD8+ T cell antigenic peptides | Q27687391 | ||
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance | Q28282405 | ||
Coordinated Evolution of Influenza A Surface Proteins | Q28547048 | ||
Rational design of potent sialidase-based inhibitors of influenza virus replication | Q29616647 | ||
Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. | Q30372482 | ||
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. | Q30390856 | ||
Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza | Q30396231 | ||
A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase | Q30405350 | ||
Influenza surveillance during the post-pandemic influenza 2010/11 season in Greece, 04 October 2010 to 22 May 2011. | Q30409510 | ||
Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. | Q30412554 | ||
Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. | Q30445738 | ||
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design | Q31440495 | ||
Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses | Q34102756 | ||
Permissive secondary mutations enable the evolution of influenza oseltamivir resistance | Q34118992 | ||
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials | Q34460803 | ||
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity | Q34565520 | ||
Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer | Q34759825 | ||
Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013-14. | Q34843761 | ||
Challenges in antigenic characterization of circulating influenza A(H3N2) viruses during the 2011-2012 influenza season: an ongoing problem? | Q35455493 | ||
Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. | Q36048315 | ||
Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season | Q37164761 | ||
Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. | Q37169942 | ||
Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites | Q37215150 | ||
P433 | issue | 2 | |
P304 | page(s) | 361-371 | |
P577 | publication date | 2016-11-15 | |
P1433 | published in | European Journal of Clinical Microbiology & Infectious Diseases | Q15754378 |
P1476 | title | Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment | |
P478 | volume | 36 |
Q58614971 | Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus |
Q40094068 | Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection |
Q91173936 | Rapid functionalisation and detection of viruses via a novel Ca2+-mediated virus-DNA interaction |
Q93160589 | Severity and outcomes of influenza-related pneumonia in type A and B strains in China, 2013-2019 |
Search more.